Quarterly ResultMay 7, 2026, 08:27 AM
Aurinia Q1 Revenue $77.7M (+24%); EPS $0.25 (+56%)
AI Summary
Aurinia Pharmaceuticals reported strong financial results for Q1 2026, with total revenue increasing 24% to $77.7 million and diluted EPS rising 56% to $0.25. Net product sales of LUPKYNIS grew 23% to $73.6 million. The company reiterated its full-year 2026 revenue and net product sales guidance and highlighted progress in its pipeline.
Key Highlights
- Total revenue for Q1 2026 was $77.7 million, up 24% from $62.5 million in Q1 2025.
- Net product sales of LUPKYNIS reached $73.6 million, a 23% increase from Q1 2025.
- Net income for Q1 2026 was $34.4 million, up 48% from $23.3 million in Q1 2025.
- Diluted earnings per share increased 56% to $0.25 from $0.16 in Q1 2025.
- Cash flows from operating activities surged 2408% to $32.6 million in Q1 2025.
- Cash, cash equivalents, and investments totaled $378.8 million as of March 31, 2026.
- Repurchased 2.5 million common shares for $36.2 million during the quarter.
- Reiterated 2026 total revenue guidance of $315 million to $325 million.